Neuronetics announced that the Pharmaceuticals and Medical Devices Agency in Japan has approved multiple proprietary innovations, which significantly advance the patient treatment experience with the NeuroStar TMS Therapy System for the treatment of major depressive disorder in Japan. The features covered in this approval include the NeuroStar 3.7 platform, MT Cap, D-Tect MT Accessory, and the Dash treatment protocol.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on STIM:
- Neuronetics to Present at the 35th Annual Piper Sandler Healthcare Conference
- Neuronetics upgrades software solutions for depression treatment
- NeuroStar Elevates Depression Treatment with Cutting-Edge Technology Advancements
- Neuronetics announces momentum from health plans for TMS therapy coverage
- Neuronetics Announces Continued Momentum from Health Plans for TMS Therapy Coverage